The A-LIST WMM Insights Series

Alzheimer Disease Clinical Trial

Official title:

A-LIST What Matters Most Insights Series

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04466722
• Other study ID #: A-LIST Protocol 1
• Status: Recruiting
• Start date: August 15, 2018
• Est. completion date: December 31, 2023

Study information

• Verified date: June 2022
• Source: UsAgainstAlzheimer's
• Contact: Virginia Biggar, BA
• Phone: 3014521123
• Email: vbiggar[@]usagainstalzheimers.org
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The main purpose of the Study is to develop an understanding over time and through multiple research projects, including surveys, interviews, online focus groups, and other primary research methodologies (A-LIST Research Projects) on what matters most to individuals concerned about brain health and those with and/or affected by Alzheimer's disease and other dementias, including caregivers.

Description:

To do this, UsAgainstAlzheimer's will identify and engage individuals who want to focus on brain health; individuals who are worried about their cognition; individuals who perceive themselves to be at risk for Alzheimer's disease (AD); individuals who may be at risk for AD due to self-identified confirmation of underlying disease pathology; individuals who self-identify as having a diagnosis of mild cognitive impairment (MCI) or of AD or another dementia; and those who self-identify as current or former caregivers of patients with Alzheimer's disease or another dementia to participate in the A-LIST Research Projects. Such participants will either already be - or will be invited to become - members of the A-LIST cohort, an online cohort of individuals ready and willing to engage in A-LIST WMM Insights Series (A-LIST members). The A-LIST WMM Insights Series will enlist participants to offer insights into a range of issues relevant to Alzheimer's, including as examples issues pertinent to clinical trial design, regulatory submissions, other research strategies, payer value determinations, and care and services research. The A-LIST WMM Insights Series may seek information that in some instances will be marketing research or other research exempt from IRB oversight. However, when an individual A-LIST Research Project constitutes human subjects research consistent with governing law, IRB approval will be sought and obtained. Where questions exist whether an individual A-LIST Research Project constitutes human subject research, IRB determination will be solicited.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

To be eligible to participate in the Study, an individual must meet all of the following

criteria:

1. Age 18 years or older.

2. United States, Canada resident.

3. Self-report of cognitive difficulties, caregiver status or interest in brain health.

4. Have indicated willingness to participate by selecting "I Agree" option when joining the A-LIST. Additionally, will have clicked on link - invitation to take a specific survey

5. Able to speak, read, and understand English. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation

in this Study:

1. Unable to comply with the Study requirements.

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction
• Dementia
• Mild Cognitive Impairment

Locations

Country	Name	City	State
United States	UsAgainstAlzheimer's	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
UsAgainstAlzheimer's

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phenotypical Characteristics of Patients and Caregivers	Online monthly surveys capture the burden and unmet needs for patients and caregivers of individuals with or at risk for Alzheimer's disease, other dementias, and mild cognitive impairment; also recruiting individuals interested in brain health.	3 years

External Links

•   Join UsAgainstAlzheimer's A-LIST